Inventiva S.A.
IVA
Rangering i aksjer
#10339
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Aksjekurs
$3.43
Markedsverdi
$809.76M
Endring (1 dag)
-0.34%
Endring (1 år)
-9.63%
Land
FR
Handel Inventiva S.A. (IVA)
Kategori
Healthcare
Historikk for aksjesplitt for Inventiva S.A. (IVA)
Aksjen Inventiva S.A. (symbol: IVA) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én IVA-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 IVA-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én IVA-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 IVA-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
